Emerging gliptins for type 2 diabetes

Bibliography

• IDF Diabetes Atlas update. 2012. Available from: http://www.idf.org/diabetesatlas/5e/Update2012 [Last accessed 14 March 2013]
   Google Scholar
• IDF Diabetes Atlas. Available from: http://www.idf.org/diabetesatlas/5e/the-global-burden [last accessed 14 March 2013]
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
   PubMed Web of Science ®Google Scholar
• Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol (Oxf) 2012;77:489-99
   PubMed Web of Science ®Google Scholar
• Vilsbøll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009;11(Suppl 3):11-18
   PubMed Web of Science ®Google Scholar
• Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73
   PubMed Web of Science ®Google Scholar
• Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4
   PubMed Web of Science ®Google Scholar
• Davidson JA. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010;85(12 Suppl):S27-37
   PubMedGoogle Scholar
• DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, et al. DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369
   PubMed Web of Science ®Google Scholar
• Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97:4605-12
   PubMed Web of Science ®Google Scholar
• Datamonitor Healthcare's Diabetes Hot Topics. Use of key non-insulin brands in the type 2 diabetes treatment algorithm. Henry C. 27 April 2012. Reference Code DMKC0053693
   Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 2011;13:144-9
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, et al. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VADT Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009;53:298-304
   PubMed Web of Science ®Google Scholar
• Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010;363:1489-91
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818-25
   PubMed Web of Science ®Google Scholar
• Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:4206-16
   PubMed Web of Science ®Google Scholar
• McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010;363:2339-50
   PubMed Web of Science ®Google Scholar
• Viereck C, Boudes P. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemp Clin Trials 2011;32:324-32
   PubMed Web of Science ®Google Scholar
• Available from: http://www.novartis.com/downloads/newsroom/corporate-fact-sheet/2a_Pharmaceuticals_EN.pdf [Last accessed 10 May 2013]
   Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
   PubMed Web of Science ®Google Scholar
• Furuta S, Smart C, Hackett A, et al. Pharmacokinetics and metabolism of [(14)C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica 2013;43:432-42
   PubMed Web of Science ®Google Scholar
• Sunami Y, Yoshioka N, Hayashi I, Ishida T. Safety, tolerability, pharmacokinetics and pharmacodynamics of SK-0403, a novel DPP-IV inhibitor, in healthy Japanese subjects [abstract 0482-P]. 67th Meet Am Diabetes Assoc; Chicago; 2007
   Google Scholar
• Suiny drug information sheet. Available from: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32790 [Last accessed 13 March 2013]
   Google Scholar
• Lim KS, Cho JY, Kim BH, et al. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br J Clin Pharmacol 2009;68:883-90
   PubMed Web of Science ®Google Scholar
• Fukuda-Tsuru S, Anabuki J, Abe Y, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 2012;696:194-202
   PubMed Web of Science ®Google Scholar
• Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14:1040-6
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; published online 6 Mar 2013; doi: 10.1111/dom.12092
   Web of Science ®Google Scholar
• Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11:1145-52
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-77
   PubMed Web of Science ®Google Scholar
• Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012;28:513-23
   PubMed Web of Science ®Google Scholar
• Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012;14:795-802
   PubMed Web of Science ®Google Scholar
• Kothny W, Foley J, Kozlovski P, et al. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:252-7
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov trial no NCT00954447
   Google Scholar
• Rhee EJ, Lee WY, Min KW, et al. Gemigliptin Study 006 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes Metab 2013;15:523-30
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012;109:1681-5
   PubMed Web of Science ®Google Scholar
• Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012;9:109-16
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl 3):57-64
   PubMed Web of Science ®Google Scholar
• van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab 2012;14:101-11
   PubMed Web of Science ®Google Scholar
• Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33:1609-29
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206
   PubMed Web of Science ®Google Scholar
• Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;2):CD006739
   PubMed Web of Science ®Google Scholar
• Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011;34:369-74
   PubMed Web of Science ®Google Scholar
• Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012;14:1061-72
   PubMed Web of Science ®Google Scholar
• Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 2012;46:1453-69
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar
• Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med 2008;358(18):1969-72
   PubMed Web of Science ®Google Scholar
• Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagon-like Peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-9
   PubMed Web of Science ®Google Scholar
• Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509
   PubMed Web of Science ®Google Scholar
• Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013;346:f2267
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov – trials identifier NCT01243424, NCT01107886, NCT00790205, NCT00894868, NCT00968708 [Last accessed 13 March 2013]
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
   PubMed Web of Science ®Google Scholar
• Novartis group annual report. 2012. Available from: http://www.novartis.com/downloads/investors/reports/annual-report-2012-financial-report-en.pdf [Last accessed 13 March 2013]
   Google Scholar
• AstraZeneca PLC Fourth quarter and full year results. 2012. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20130131–astrazeneca-2012-fourth-quarter-and-full-year-results [Last accessed 13 March 2013]
   Google Scholar
• Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results. Available from: http://www.merck.com/investors/financials/4Q12SERelease-01-02-2013.pdf [Last accessed 13 March 2013]
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Sales of major products. Available from: http://www.takeda.com/investor-information/highlights/products.html [Last accessed 13 March 2013]
   Google Scholar
• Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9
   PubMed Web of Science ®Google Scholar
• Nagakura T, Yasuda N, Yamazaki K, et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001;284:501-6
   PubMed Web of Science ®Google Scholar
• Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004;53:1326-35
   PubMed Web of Science ®Google Scholar
• Kos K, Baker AR, Jernas M, et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 2009;11:285-92
   PubMed Web of Science ®Google Scholar
• Aaboe K, Knop FK, Vilsbøll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010;12:323-33
   PubMed Web of Science ®Google Scholar
• Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33:1607-9
   PubMed Web of Science ®Google Scholar
• Theiss HD, Brenner C. Engelmann et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)–rationale, design and first interim analysis. Int J Cardiol 2010;145:282-4
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25
   PubMed Web of Science ®Google Scholar
• Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens 2012;6:163-8
   PubMed Web of Science ®Google Scholar
• Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48:592-8
   PubMed Web of Science ®Google Scholar
• Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010;56:728-33
   PubMed Web of Science ®Google Scholar
• Pharmaprojects - copyright to Citeline Drug Intelligence (an informa business) search results: evogliptin, melogliptin, gosogliptin, omargliptin, trelagliptin
   Google Scholar
• Gantz I, Chen M, Mirza A, et al. Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12 weeks in patients with type 2 diabetes mellitus [Presentation no. 110]. 48th EASD Annual Meeting; Berlin; 2012
   Google Scholar
• TODAY Study Group. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247-56
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov trials identifier NCT00730275, NCT00957268, NCT01342484, NCT01525225
   Google Scholar
• Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35:2650-64
   PubMed Web of Science ®Google Scholar
• Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30:3017-22
   PubMed Web of Science ®Google Scholar
• Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58
   PubMed Web of Science ®Google Scholar
• Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34:1463-8
   PubMed Web of Science ®Google Scholar
• Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009;32:2251-7
   PubMed Web of Science ®Google Scholar
• Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77-84
   PubMed Web of Science ®Google Scholar
• Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013;19:19-28
   PubMed Web of Science ®Google Scholar
• Farngren J, Persson M, Schweizer A, et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 2012;97:3799-806
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov trial no NCT01155284
   Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708
   PubMed Web of Science ®Google Scholar
• Thrasher J, Daniels K, Patel S, Whetteckey J. Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin. Expert Opin Pharmacother 2012;13:2443-52
   PubMed Web of Science ®Google Scholar